Amgen (AMGN) Offering Possible 10.86% Return Over the Next 10 Calendar Days

This article was originally published on this site

Amgen’s most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $177.50 short call and a strike $182.50 long call offers a potential 10.86% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $177.50 by expiration. The full premium credit of $0.49 would be kept by the premium seller. The risk of $4.51 would be incurred if the stock rose above the $182.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.

The RSI indicator is at 39.12 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday
Sat, 05 Aug 2017 15:52:00 +0000
Valeant Pharmaceuticals is expected to earn $0.97/share on $2.24 billion in revenue. Meanwhile, the so-called Whisper number is $1.01.

The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise
Thu, 03 Aug 2017 20:23:47 +0000
Regeneron dove to a seven-week low Thursday as light revenue from an eczema drug weighed on the stock despite a broader second-quarter beat-and-raise.

Earnings Preview: What To Expect From Teva Pharmaceutical On Thursday
Wed, 02 Aug 2017 15:01:00 +0000
Teva is expected to report earnings of $1.06 per share on $5.85 billion in revenue. Meanwhile, the so-called Whisper number is $1.08.

Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote
Wed, 02 Aug 2017 12:32:12 +0000
Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.

3 ETFs to Watch Out for on Biotech Earnings
Tue, 01 Aug 2017 04:26:04 +0000
Major players in the biotech space reported their second quarter 2017 results.

Be Sociable, Share!

Related Posts